Hint mode is switched on Switch off

Daiichi Sankyo, ordinary share
JP3475350009, 4568

Add a stock to WL
Choose all Reset all
Daiichi Sankyo, сountry — Japan
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Latest quotes

explore the most comprehensive database

800 000

bonds globally

Over 400

pricing sources

80 000

stocks

9 000

ETF

track your portfolio in the most efficient way
Bond Search
Watchlist
Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Issuer

Profile
Daiichi Sankyo Company, Limited (第一三共株式会社 Daiichi Sankyō Kabushiki-kaisha?) is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 1,148.2 billion in revenue in 2013. The company owns the American biotechnology ...
Daiichi Sankyo Company, Limited (第一三共株式会社 Daiichi Sankyō Kabushiki-kaisha?) is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 1,148.2 billion in revenue in 2013. The company owns the American biotechnology company Plexxikon, the German biotechnology company U3 Pharma and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
Show more Hide
  • Issuer
  • Full borrower / issuer name
    Daiichi Sankyo Company, Limited
  • Industry
    Pharmaceutical Preparation and Biotechnology

Related Stock indices

Indicators

News

20/02/2023 Moody's Investors Service affirms Daiichi Sankyo at "A2" (LT- foreign currency credit rating); outlook stable
20/02/2023 Moody's Investors Service affirms Daiichi Sankyo at "A2" (LT- local currency credit rating); outlook stable
17/02/2023 Moody's affirms Daiichi Sankyo's A2 rating; outlook stable   (Rating action commentary)
04/08/2020 Moody's Investors Service affirms Daiichi Sankyo at "A2" (LT- foreign currency credit rating); outlook stable
04/08/2020 Moody's Investors Service affirms Daiichi Sankyo at "A2" (LT- local currency credit rating); outlook stable
All organization news

Domestic and international bonds of the issuer

Holders

Industry Leaders

Registration is required to get access.